This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cachofeiro, V. Articles by Lahera, V. Search for Related Content PubMed PubMed Citation Articles by Cachofeiro, V. Articles by Lahera, V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE INDOMETHACIN LOSARTAN POTASSIUM NITRIC OXIDE Medline Plus Health Information High Blood Pressure

(Hypertension. 1995;26:236-243.)
© 1995 American Heart Association, Inc.

Articles

Nitric Oxide and Prostaglandins in the Prolonged Effects of Losartan and Ramipril in Hypertension

Victoria Cachofeiro; Rosaura Maeso; Elena Rodrigo; Josefa Navarro; Luis M. Ruilope; Vicente Lahera

From the Department of Physiology, Complutense University, Medical School, Madrid, Spain.

Correspondence to V. Cachofeiro, Departamento de Fisiología, Facultad de Medicina, Universidad Complutense, Madrid 28040, Spain.

Abstract We investigated the role of endogenous nitric oxide, kinins, and prostaglandins in the vasodepressor and renal excretory effects of the angiotensin II receptor antagonist losartan and the angiotensin-converting enzyme inhibitor ramipril administered for 1 week to spontaneously hypertensive rats. To this end, either losartan (10 mg/kg per day) or ramipril (2.5 mg/kg per day) was administered in drinking water with or without simultaneous administration of (1) the nitric oxide synthesis inhibitor N^G-nitro-L-arginine methyl ester (L-NAME, 6 mg/kg per day), (2) the cyclooxygenase inhibitor indomethacin (5 mg/kg per day), (3) the bradykinin B₂ receptor antagonist Hoe 140 (0.5 mg/kg per day SC), or (4) L-NAME plus indomethacin. Both losartan and ramipril significantly reduced blood pressure as measured by the tail-cuff method. L-NAME increased blood pressure when administered solely or in combination with losartan. However, L-NAME attenuated the hypotensive effect of ramipril. Indomethacin did not affect blood pressure but it reduced the antihypertensive action of losartan and ramipril. Indomethacin administration did not potentiate the increase in blood pressure induced by L-NAME. However, the concurrent administration of both inhibitors almost totally blunted the vasodepressor action of ramipril. By contrast, losartan administration in the presence of L-NAME and indomethacin increased blood pressure to a level similar to that after losartan plus L-NAME. Hoe 140 did not modify either blood pressure or the hypotensive effects of losartan or ramipril. Increases in diuresis and water intake were observed during ramipril administration. Both effects were blunted only with the concurrent administration of L-NAME and indomethacin. None of the cotreatments were able to modify renal excretory function by themselves. These data suggest a contribution of endogenous nitric oxide and prostaglandins but not of kinins in the prolonged antihypertensive effect of both losartan and ramipril in the spontaneously hypertensive rat.

Key Words: nitric oxide • prostaglandins • kinins • angiotensin receptors • angiotensin-converting enzyme inhibitors • blood pressure • kidney function

This article has been cited by other articles:

				M. Moreno, L. N. Ramalho, P. Sancho-Bru, M. Ruiz-Ortega, F. Ramalho, J. G. Abraldes, J. Colmenero, M. Dominguez, J. Egido, V. Arroyo, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G147 - G156. [Abstract] [Full Text] [PDF]

				N. de las Heras, M. Ruiz-Ortega, M. Ruperez, D. Sanz-Rosa, M. Miana, P. Aragoncillo, S. Mezzano, V. Lahera, J. Egido, and V. Cachofeiro Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 192 - 200. [Abstract] [PDF]

				J. Gimenez, P. M Garcia, B. Bonacasa, L. F Carbonell, T. Quesada, and I. Hernandez Effects of oestrogen treatment and angiotensin-converting enzyme inhibition on the microvasculature of ovariectomized spontaneously hypertensive rats Exp Physiol, January 1, 2006; 91(1): 261 - 268. [Abstract] [Full Text] [PDF]

				H. Thai, J. Wollmuth, S. Goldman, and M. Gaballa Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1171 - 1178. [Abstract] [Full Text] [PDF]

				E. Cediel, D. Sanz-Rosa, M. P. Oubina, N. de las Heras, F. R. G. Pacheco, O. Vegazo, J. Jimenez, V. Cachofeiro, and V. Lahera Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R674 - R681. [Abstract] [Full Text] [PDF]

				L. Kalinowski, T. Matys, E. Chabielska, W. Buczko, and T. Malinski Angiotensin II AT1 Receptor Antagonists Inhibit Platelet Adhesion and Aggregation by Nitric Oxide Release Hypertension, October 1, 2002; 40(4): 521 - 527. [Abstract] [Full Text] [PDF]

				H. Han, S. Hoffmann, K. Hu, and G. Ertl Angiotensin II subtype 1 (AT1) receptors contribute to ischemic contracture and regulate chemomechanical energy transduction in isolated transgenic rat ({alpha}MHC-hAT1)594-17 hearts Eur J Heart Fail, March 1, 2002; 4(2): 131 - 137. [Abstract] [Full Text] [PDF]

				I. Kucharewicz, E. Chabielska, D. Pawlak, T. Matys, R. Rolkowski, and W. Buczko The antithrombotic effect of angiotensin-(1--7) closely resembles that of losartan Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 268 - 272. [Abstract] [PDF]

				K. Inoue, H. Nishimura, J. Kubota, and Y. Kitaura Nitric oxide mediates inhibitory effect of losartan on angiotensin-induced contractions in hamster but not rat aorta Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 180 - 183. [Abstract] [PDF]

				J. Kalliovalkama, P. Jolma, J.-P. Tolvanen, M. Kahonen, N. Hutri-Kahonen, X. Wu, P. Holm, and I. Porsti Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism Cardiovasc Res, June 1, 1999; 42(3): 773 - 782. [Abstract] [Full Text] [PDF]

				K. Yamada, S. N. Iyer, M. C. Chappell, D. Ganten, and C. M. Ferrario Converting Enzyme Determines Plasma Clearance of Angiotensin-(1–7) Hypertension, September 1, 1998; 32(3): 496 - 502. [Abstract] [Full Text] [PDF]

				C. Richer, P. Bruneval, J. Menard, and J.-F. Giudicelli Additive Effects of Enalapril and Losartan in (mREN-2)27 Transgenic Rats Hypertension, February 1, 1998; 31(2): 692 - 698. [Abstract] [Full Text] [PDF]

				P. Li, C. M. Ferrario, and K. B. Brosnihan J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1065 - 1070. [Abstract] [Full Text]

				R. Maeso, J. Navarro-Cid, R. Munoz-Garcia, E. Rodrigo, L. M. Ruilope, V. Lahera, and V. Cachofeiro Losartan Reduces Phenylephrine Constrictor Response in Aortic Rings From Spontaneously Hypertensive Rats: Role of Nitric Oxide and Angiotensin II Type 2 Receptors Hypertension, December 1, 1996; 28(6): 967 - 972. [Abstract] [Full Text]